Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews -- Be empowered with MS news by registering with us: www.register.msviewsandnews.org

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

============================================================

Wednesday, November 11, 2015

Novartis' MS Drug Gilenya Prevents Activation of Key Immune Cells in Study


<span class="entry-title">Novartis’ MS Drug Gilenya Prevents Activation of Key Immune Cells in Study</span><span class="entry-subtitle">Study focus on immunosuppressive actions of the drug fingolimod</span>

In a recent study entitled “Myeloid cells as target of fingolimod action in multiple sclerosis,” a team of scientists investigated the impact of fingolimod (GilenyaNovartis), an approved drug for multiple sclerosis (MS), on the reactivity of myeloid cells, a key group that comprises several immune cells that are activated in MS patients and the underlying cause of the disease. The study was published in the journal Neurology.
MS is an autoimmune disease that affects the central nervous system and afflicts more than 2.3 million people in the world. Currently without a cure, the disease is characterized by the destruction of the myelin layer within nerve cells. This leads to a wide range of neurological symptoms affecting visual, motor, and sensory capabilities.
Fingolimod is one of the few treatments for MS and is an analogue of a cellular key protein called sphingosine. When added to cells, fingolimod binds sphingosine-1-phosphate (S1P) receptors and promote their degradation. Since S1P receptors are important for immune cells’ trafficking to the central nervous system, fingolimod reduces this trafficking and is thus associated with reducing MS-disease relapse and disability progression.
Researchers investigated how fingolimod influences the activation of myeloid cells from the periphery to the central nervous system. (Myeloid cells originate in the bone marrow or spinal cord and include several key cells in our immune system, such as monocytes, macrophages, neutrophils, basophils, eosinophils, erythrocytes, dendritic cells, and megakaryocytes or platelets.) The team analyzed how fingolimod interfered with the activation of immune cells in vitro and later performed further studies where administration of fingolimod during experimental autoimmune encephalomyelitis (a disease model of human MS) was used to assess its effects on the activation of splenic, central nervous system infiltrating, and central nervous system resident myeloid cells.
~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~~
MS Views and News helps to provide information for all affected by MS
Keep up to date with the news and information we provide 
by signing up by clicking here
.===================================

No comments: